GET DAILY SIGNALSMyomo (MYO) Stock Declines -16.6% Over 30 Days as Post-Earnings Gains Unwind
Key Takeaways
- MYO shares have declined roughly 16.6% over the trailing 30 days, falling from about $1.45 to $1.21 as a mid-August rally continued to unwind.
- The pullback extends a broader fade from the multi-month peak near $1.86 reached after strong second-quarter results in early August.
- No single earnings event drove the recent slide; the move reflects profit-taking, elevated micro-cap volatility, and cautious positioning ahead of third-quarter results.
- Underlying fundamentals remain supported by expanding reimbursement coverage, new distribution through Ottobock Care clinics, and a growing mix of recurring revenue sources.
- Myomo is still unprofitable, and the stock carries elevated volatility and relatively thin trading liquidity, which can amplify short-term swings.
- Investors can review Myomo's Price Targets, Earnings, and Forecast for additional data and analysis on dedicated pages.
Myomo's Focus on Wearable Medical Robotics
Myomo, Inc. is a wearable medical robotics company headquartered in Burlington, Massachusetts, listed on the NYSE American exchange. The company develops and markets the MyoPro product line, a powered upper-limb orthosis — a custom-fabricated arm brace — that reads a patient's own electromyography (EMG) signals through non-invasive sensors and uses lightweight motors to restore movement to weakened or paralyzed arms.
MyoPro is registered with the U.S. Food and Drug Administration as a Class II medical device and is the only marketed device in the U.S. that senses a patient's own EMG signals to help restore the ability to perform daily activities such as feeding, carrying objects, and household tasks. It serves people affected by stroke, brachial plexus injury, spinal cord or traumatic brain injury, and other neuromuscular conditions.
Myomo generates revenue by selling directly to patients while billing insurers, through orthotics and prosthetics (O&P) providers, to the Veterans Health Administration, and internationally. I am watching the stock because of its expanding reimbursement coverage — covered lives have grown from roughly 9 million to about 158 million since Medicare coverage began in April 2024 — and its stated path toward operating leverage and profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action in MYO Shares
Over the trailing 30 days, MYO has fallen about 16.6%, from a closing price near $1.45 to roughly $1.21. The decline was not a single sharp event but a steady drift lower as earlier gains were given back.
The picture over the last quarter is more nuanced. Shares entered the period near $1.31 in early August, surged to a multi-month peak near $1.86 in mid-August following second-quarter results, and then faded. Measured from the early-August level of about $1.31, the stock is down roughly 8% over the past three months — a decline that largely reflects the reversal of a post-earnings spike rather than a sustained deterioration in the underlying business.
Factors Behind the 30-Day Move
The recent 30-day decline did not stem from a single earnings report or major negative catalyst. Instead, it reflects a gradual unwind of the August rally, profit-taking after a sharp run, and the elevated volatility typical of a sub-$100 million market-capitalization stock with relatively thin liquidity.
During the period, Myomo named Mary-Katherine McClure as its Chief Commercial Officer, a leadership addition rather than a financial event. Third-party risk-monitoring services also flagged heightened share-price volatility and modest insider selling over the prior months, factors that can weigh on short-term sentiment for micro-cap equities. With third-quarter results scheduled for early-to-mid November, traders also appeared to position cautiously ahead of the company's next earnings update and any revision to full-year guidance.
Performance Drivers Over the Past Quarter
The quarter's defining event was Myomo's second-quarter report. Revenue rose 21% year over year to about $11.7 million, exceeding estimates, while gross margin expanded to 72.1% and adjusted EBITDA improved materially. Management raised full-year 2026 revenue guidance to a range of $45 million to $47 million, and the stock rallied sharply in response, climbing from roughly $1.06 in early August to a peak near $1.86 by mid-August.
As the quarter progressed, however, shares gave back most of those gains. Investors weighed the company's continued net losses against a longer-term profitability timeline, while macro pressures on Medicare Advantage plans and the inherent lumpiness of a multi-quarter reimbursement cycle tempered enthusiasm. The result was a multi-month fade that left the stock below its pre-rally level by early November.
Key Areas to Monitor Going Forward
Several factors are likely to shape Myomo's outlook. Third-quarter earnings and any update to full-year revenue guidance are the most immediate focal points. Investors will also watch the company's reimbursement progress, including additional state contracts under its Elevance Health arrangement and further expansion of covered lives, as well as the rollout of the MyoPro through Ottobock Care clinics.
Product and clinical milestones matter as well. Development of the next-generation MyoPro 3 platform and six-month data from the University of Utah randomized controlled trial could influence payer coverage and long-term demand. Internationally, Myomo's German expansion and a planned hand-only device address a larger addressable market. Finally, the company's ability to demonstrate operating leverage, narrow losses, and reduce cash burn remains central to how the stock is valued. From what I see, this is important because sustained progress here could support a more durable valuation.
AI-Powered Trading Strategies Worth Considering
In my view, tools like Tickeron’s Trending AI Robots can provide useful context when evaluating stocks such as MYO. The page curates a selection of automated trading bots from a platform that offers hundreds of AI-driven robots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, making it a focused starting point for traders evaluating systematic strategies. The bots vary widely in approach, timeframe, and performance metrics, so users can compare different methodologies before choosing one that aligns with their objectives. I find this helpful for complementing fundamental research with algorithmic signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MYO in upward trend: price may jump up because it broke its lower Bollinger Band on October 13, 2026
MYO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MYO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MYO's RSI Oscillator exited the oversold zone, 30 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where MYO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MYO as a result. In 61 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for MYO just turned positive on November 03, 2026. Looking at past instances where MYO's MACD turned positive, the stock continued to rise in 27 of 40 cases over the following month. The odds of a continued upward trend are 68%.
Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYO advanced for three days, in 197 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
MYO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MYO crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MYO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.221) is normal, around the industry mean (4.142). P/E Ratio (-3.559) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.262) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. MYO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of neuro-robotic technology
Industry MedicalNursingServices
Advertisement